According to Jin10, BioNTech SE (BNTX.O) fell about 10% in U.S. pre-market trading after the company announced it had ended its Phase 2 Cevumeran cancer immunotherapy trial.
Artículo
BioNTech Shares Fall About 10% Pre-Market After Ending Phase 2 Cevumeran Cancer Immunotherapy Trial
--・
Aviso legal: Incluye opiniones de terceros. No debe interpretarse como asesoramiento. Binance AI puede usarse sin garantía. Lee los TyC.